REGENERON PHARMACEUTICALS Business Summary

Regeneron Pharmaceuticals, Inc. (REGN) operates as a fully integrated biopharmaceutical leader that generates revenue through the commercialization of proprietary monoclonal antibody therapies and significant collaboration profit-sharing. Its financial model is primarily driven by net product sales from its core franchises—Ophthalmology (Eylea HD, Eylea), Immunology (Dupixent), and Oncology (Libtayo)—alongside substantial collaboration revenue from strategic partners Sanofi and Bayer. The company’s business is segmented by therapeutic area, with an expanding footprint in hematology and rare diseases supported by its proprietary VelociSuite® technology platforms. Regeneron maintains a dominant market position in retinal diseases and type 2 inflammatory conditions, competing directly with global giants such as Roche, Amgen, Gilead Sciences, and Moderna. The company distinguishes itself through a high-density internal R&D engine and the Regeneron Genetics Center, positioning it as a primary innovator relative to competitors that rely more heavily on external acquisitions. Founded in 1988, Regeneron is led by its original visionary duo: Dr. Leonard S. Schleifer, Co-Founder, President, and CEO, and Dr. George D. Yancopoulos, Co-Founder, Board Co-Chair, President, and Chief Scientific Officer. Schleifer, a neurologist with a PhD from the University of Virginia and a former professor at Weill Cornell Medical School, established the company’s strategic and commercial foundation, while Yancopoulos, a Columbia University-trained MD/PhD and one of the world’s most cited scientists, serves as the primary architect of its drug discovery engine. The executive leadership team also includes Christopher Fenimore as EVP and Chief Financial Officer and Marion McCourt as EVP of Commercial Operations. The company’s Board of Directors features distinguished scientific and business figures, including Dr. Bonnie Bassler and Dr. Huda Zoghbi, while major institutional investors include BlackRock, Vanguard, and FMR LLC, reflecting its status as a staple in large-cap healthcare portfolios.